Psoriasis News

THE LATEST FROM IPC, INDUSTRY AND OTHERS

Results

Psoriasis and the Pandemic: Lessons Learned from PsoProtect

The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.

Friday, May 26, 2023

Smiling photos of Drs. de la Cruz and Armijo with the title of the post on a yellow background

Prioritizing the Patient Perspective in Psoriasis Care and Communications

The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.

Wednesday, January 18, 2023

Revised IPC Statement on COVID-19

This revised statement is based on expert opinion and should be interpreted in the context of local policies and emerging evidence.

Monday, December 19, 2022

PsoProtect Registry Data Update

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases.

Wednesday, June 15, 2022

Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic

The COVID-19 pandemic has been a significant concern, and vaccination has been crucial worldwide in its combat.

Wednesday, May 11, 2022

Commentary: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

A research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity.

Tuesday, January 25, 2022

Latin American Case Series

It is not fully understood the impact that COVID-19 has on psoriasis patients.

Wednesday, January 19, 2022

Commentary: Coronavirus disease 2019 (COVID‐19)‐associated hospitalization and mortality in patients with psoriasis: A population‐based study

The safety of treatment for immune-mediated diseases like psoriasis during the COVID-19 pandemic is a matter of concern. In an Israeli population-based nested case-control study using the Clalit Health Services database, 3,151 patients with psoriasis that tested positive for SARS-CoV-2 infection were identified.

Wednesday, July 7, 2021

Commentary: Sex differences in immune responses that underlie COVID-19 disease outcomes

Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection, the IMPACT Research Team from Yale University investigated sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.

Monday, May 17, 2021

Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19

An article recently published in the Journal of Allergy and Clinical Immunology suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%. The authors of the study (Lam Tsoi and collaborators, University of Michigan) examined the medical records of 435,000 individuals, 1,115 of whom had been diagnosed with COVID-19.

Monday, February 8, 2021

Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion

In a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments.

Tuesday, February 2, 2021

Commentary: NPF COVID-19 Task Force Guidance Statements

Recently, the Task Force (TF) of the National Psoriasis Foundation (NPF) released a revised version of its COVID-19 statement after an in-depth analysis of publicly available data with two currently approved anti-SARS-CoV-2 vaccines in the US, both mRNA-based.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Advancing Knowledge. Enhancing Care.

Psoriasis News

Psoriasis and the Pandemic: Lessons Learned from PsoProtect

Prioritizing the Patient Perspective in Psoriasis Care and Communications

Revised IPC Statement on COVID-19

PsoProtect Registry Data Update

Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic

Commentary: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

Latin American Case Series

Commentary: Coronavirus disease 2019 (COVID‐19)‐associated hospitalization and mortality in patients with psoriasis: A population‐based study

Commentary: Sex differences in immune responses that underlie COVID-19 disease outcomes

Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19

Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion

Commentary: NPF COVID-19 Task Force Guidance Statements

New Resources

Psoriasis Treatment and Chronic Infections (Webinar 2, 2023 Series)

Psoriasis and Cancer: Epidemiologic Association (Webinar 2, 2023 Series)

Psoriasis Treatment and Cancer: New Perspectives (Webinar 2, 2023 Series)

Subscribe to the IPC Newsletter

Quick Links

Follow us